Physician profile
Faisal Wasi
NPI 1689672263
$2,247.81
in general payments reported to CMS, 2019-2025
29 companies · $50.86 in 2025
The $50.86 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $585 · 2020: $478 · 2021: $229 · 2022: $273 · 2023: $403 · 2024: $228 · 2025: $50.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $682.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $682.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $295.48 | 2021-2024 | Avycaz, Teflaro, Dalvance |
| Merck Sharp & Dohme LLC | $249.59 | 2019-2024 | Recarbrio, Dificid, Zerbaxa |
| Gilead Sciences, INC. | $206.30 | 2019-2020 | |
| Allergan, INC. | $193.21 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $170.52 | 2020-2024 | Nuzyra |
| Melinta Therapeutics, LLC | $152.80 | 2019-2020 | |
| La Jolla Pharmaceutical Company | $151.74 | 2021-2023 | Xerava |
| Viiv Healthcare Company | $144.11 | 2022-2024 | Dovato |
| Ferring Pharmaceuticals INC. | $123.95 | 2023 | Rebyota |
| Glaxosmithkline, LLC. | $76.02 | 2019-2022 | |
| Astellas Pharma US INC | $68.49 | 2019-2024 | Cresemba |
| Sunovion Pharmaceuticals INC. | $64.42 | 2019-2020 | |
| Novo Nordisk INC | $43.14 | 2019-2020 | |
| Shionogi INC | $41.92 | 2024-2025 | Fetroja |
| Dexcom, INC. | $36.75 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $30.25 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $23.17 | 2025 | Zenpep |
| Daiichi Sankyo INC. | $21.86 | 2019 | |
| Insmed, INC. | $18.80 | 2021 | |
| Mayne Pharma Commercial LLC | $18.28 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $16.01 | 2020 | |
| Currax Pharmaceuticals LLC | $14.03 | 2024 | Contrave |
| Intra-Sana Laboratories | $13.52 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Endo Pharmaceuticals INC. | $12.92 | 2019 | |
| Lilly USA, LLC | $12.87 | 2019 | |
| Abbott Laboratories | $12.82 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.33 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $11.61 | 2019 | |
| Amgen INC. | $10.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faisal Wasi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.